Meeting
2024 ASCO Annual Meeting
Early opioid exposure (EOE) and impaired efficacy in patients with advanced NSCLC treated with PD-L1 inhibition: A pooled post hoc analysis of the POPLAR and OAK trials.
Authors
Alessio Cortellini
Division of Surgery and Cancer, Imperial College, London, United Kingdom
Alessio Cortellini , Valentina Santo , Leonardo Brunetti , Davide Mangani , Ana C Anderson , Bruno Vincenzi , Giuseppe Tonini , Kazuki Takada , Abdul Rafeh Naqash , Biagio Ricciuti , David James Pinato
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Monotherapy
Clinical Trial Registration Number
NCT02008227 and NCT01903993
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 2607)
DOI
10.1200/JCO.2024.42.16_suppl.2607
Abstract #
2607
Poster Bd #
86
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Differential prognostic effect of systemic inflammation in patients with NSCLC treated with immunotherapy or chemotherapy: A post hoc analysis of the phase III OAK trial.
First Author: Alessio Cortellini
Poster
2019 ASCO Annual Meeting
Efficacy and a novel clinicopathologic-genomic nomogram of atezolizumab in advanced non-small cell lung cancer (POPLAR and OAK): A combined analysis of two multicenter, randomized, phase II/III trials.
First Author: Yunfang Yu
Poster
2022 ASCO Annual Meeting
Impact of cancer susceptibility gene (CSG) mutations in advanced NSCLC (aNSCLC).
First Author: Danielle Klingberg
Poster
2020 Genitourinary Cancers Symposium
Genitourinary oncology referral patterns to the cancer associated thrombosis clinic: The Cleveland Clinic experience.
First Author: Iris Yeong- Fung Sheng